NEW YORK (GenomeWeb) – Metabolon said today that it has raised $15 million from new investor and healthcare growth equity firm Essex Woodlands.

The metabolomics firm said it will use the proceeds to develop and commercialize its pipeline of metabolomics technology-based precision medicine products. Essex also has the option to increase its investment by an additional $10 million, which would be used to repurchase shares from existing investors, Metabolon added. As part of the financing, Essex Managing Director Scott Barry will join Metabolon's board.  

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.